Abiraterone acetate/niraparib - Janssen
Alternative Names: AKEEGA; CJNJ-67652000Latest Information Update: 09 Jul 2025
At a glance
- Originator Janssen
- Class Androstenols; Antiandrogens; Antineoplastics; Benzamides; Indazoles; Phenanthrenes; Piperidines; Pyridines; Small molecules
- Mechanism of Action CYP17A1 protein inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Prostate cancer
Most Recent Events
- 03 Jul 2025 Preregistration for Prostate cancer (Combination therapy, Metastatic disease) in European Union (PO)
- 03 Jul 2025 Registered for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in United Kingdom (PO)
- 03 Jun 2025 Efficacy and adverse event data from a phase III AMPLITUDE trial in Prostate cancer released by Johnson and Johnson